Love them or hate them, most Americans pay their fair share of taxes into the government’s coffers as a basic duty. In return, we get roads, schools, law enforcement, health services, clean air and water and other public goods that benefit everyone.
But for too long,
The national organizations leading the push for lower prescription drug prices today sent a joint letter to Congress calling on them to pass legislation to lower prescription drug prices by passing H.R. 3, the Lower Drug Costs Now Act, this year.
AARP and more than a dozen other patient advocacy organizations have signed onto a letter asking members of Congress to support H.R. 3, the House Democrats’ drug price negotiation bill.
The letter, organized by advocacy groups Lower Drug Prices Now and Patients for Affordable Drugs,
In the first three months of the year, the pharmaceutical industry spent $92 million lobbying against efforts to protect people from their profiteering. It’s shameful. The fact is, prescription medicines and COVID vaccines can only work if people have affordable access to them. Clearly, that’s not the priority for Big Pharma players, who are more interested in protecting their monopoly patents than saving lives across the globe.
Today, the Biden Administration made clear that the United States will lead by example in the global fight against COVID. This fight can only be won by working together, not allowing the pharmaceutical corporations to dictate who gets access to COVID vaccines and when.
Action to lower drug prices is the last thing Big Pharma wants from lawmakers. Today’s hearing, which includes testimony from patients and healthcare advocates, represents a key step to enacting long-overdue reforms that would increase transparency, accountability and affordability for patients everywhere.
WASHINGTON (AP) — President Joe Biden’s call for authorizing Medicare to negotiate lower prescription drug prices has energized Democrats on a politically popular idea they’ve been pushing for nearly 20 years only to encounter frustration.
But they still lack a clear path to enact legislation.